Old Web
English
Sign In
Acemap
>
authorDetail
>
Pascal Edrich
Pascal Edrich
Novartis
Medicine
Nilotinib
Philadelphia Chromosome Positive
Immunology
Imatinib
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Early Molecular Response (EMR) with Frontline Treatment Is a Significant Predictor of Long-Term BCR-ABL Transcript Levels in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML) in Chronic Phase
2015
Blood
Giuseppe Saglio
Sonya J. Snedecor
Xiang Ji
Ming-Hui Tai
David Ray
Estella Mendelson
Aby Buchbinder
Pascal Edrich
François-Xavier Mahon
Show All
Source
Cite
Save
Citations (0)
Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model
2015
Blood
François-Xavier Mahon
An Tran-Duy
Raechelle G. Ocampo
David Ray
Estella Mendelson
Aby Buchbinder
Pascal Edrich
Sonya J. Snedecor
Giuseppe Saglio
Show All
Source
Cite
Save
Citations (0)
Everolimus treatment of subependymal giant cell astrocytomas (SEGA's) associated with tuberous sclerosis complex (TSC): the EXIST-I trial.
2011
Neuro-oncology
Steven P. Sparagana
Elena Belousova
Sergiusz Jóźwiak
Bruce R. Korf
Michael Frost
Rachel Kuperman
Michael Kohrman
Olaf Witt
Jianqiang Wu
Robert Flamini
Anna Jansen
P. Curtalolo
Elizabeth A. Thiele
Vicky Whittemore
Petrus J. de Vries
James Ford
Gaurav D. Shah
Helene Cauwel
Pascal Edrich
Tarek Sahmoud
David Neal Franz
Show All
Source
Cite
Save
Citations (0)
1